2015
DOI: 10.1016/j.jbiosc.2014.10.025
|View full text |Cite
|
Sign up to set email alerts
|

Crystal structure of streptavidin mutant with low immunogenicity

Abstract: We previously created a low-immunogenic core streptavidin mutant No. 314 (LISA-314) by replacing six amino-acid residues for use as a delivery tool for an antibody multistep pre-targeting process (Yumura et al., Protein Sci., 22, 213-221, 2013). Here, we performed high-resolution X-ray structural analyses of LISA-314 and wild-type streptavidin to investigate the effect of substitutions on the protein function and the three-dimensional structure. LISA-314 forms a tetramer in the same manner as wild-type strepta… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
12
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 15 publications
(12 citation statements)
references
References 35 publications
0
12
0
Order By: Relevance
“…Amino-acid sequences in the binding pocket of LISA314 in order to increase its affinity to an artificial analogue, iminobiotin using SBDD. 13,16,17)…”
Section: Structure-based Drug Design Of Cupid and Psychementioning
confidence: 99%
See 2 more Smart Citations
“…Amino-acid sequences in the binding pocket of LISA314 in order to increase its affinity to an artificial analogue, iminobiotin using SBDD. 13,16,17)…”
Section: Structure-based Drug Design Of Cupid and Psychementioning
confidence: 99%
“…11) Using structure-based drug design and human proteome knowledge, a low immunogenic streptavidin has been designed and proved to be less antigenic in primates after repeated injection. 12,13) The other problem is that human plasma contains a significant amount of biotin as an essential vitamin. Biotin is an important component of enzymes involved in metabolizing fats and carbohydrates, and is present in human plasma, which may cause background problems in the clinical use of streptavidin.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The 100 nm FNDs, on the other hand, increased in size by 11.3 nm upon PEGylation, suggestive of a slightly collapsed conformation of the PEG spacer arm after conjugation. SA is approximately 5 nm across its largest dimension (PDB 3WYP 25 ), thus a size increase of ~10 nm would be expected after its conjugation if SA adopted an ‘exposed’ configuration as depicted in Fig. 1ai .…”
Section: Resultsmentioning
confidence: 99%
“…For example, to reduce the immunogenicity of SA in clinical use, a low immunogenic SA mutant has been designed and structurally investigated56. Similarly, despite the high affinity of biotin-streptavidin, biotin dissociation results from low endosomal pH7 or being attached to nanoparticles8.…”
mentioning
confidence: 99%